Retacrit - NDC Database

13 records found
Page:1
0069-1305 Jun 18, 2018
Retacrit 2000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Pfizer Laboratories Div Pfizer Inc
0069-1306 Jun 18, 2018
Retacrit 3000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Pfizer Laboratories Div Pfizer Inc
0069-1307 Jun 18, 2018
Retacrit 4000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Pfizer Laboratories Div Pfizer Inc
0069-1308 Jun 18, 2018
Retacrit 10000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Pfizer Laboratories Div Pfizer Inc
0069-1309 Jun 18, 2018
Retacrit 40000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Pfizer Laboratories Div Pfizer Inc
0069-1311 Nov 09, 2020
Retacrit 20000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Pfizer Laboratories Div Pfizer Inc
0069-1318 Nov 09, 2020
Retacrit 10000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Pfizer Laboratories Div Pfizer Inc
59353-002 Jun 18, 2018
Retacrit 2000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Vifor (International) Inc.
59353-003 Jun 18, 2018
Retacrit 3000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Vifor (International) Inc.
59353-004 Jun 18, 2018
Retacrit 4000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Vifor (International) Inc.
59353-010 Jun 18, 2018
Retacrit 10000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Vifor (International) Inc.
59353-120 Sep 11, 2020
Retacrit 20000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Vifor (International) Inc.
59353-220 Sep 11, 2020
Retacrit 10000 [Iu]/Ml Intravenous; Subcutaneous Injection, Solution by Vifor (International) Inc.
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.